All University of North Carolina, Chapel Hill articles
-
News
Two-dose recombinant shingles vaccine is effective even accounting for prior receipt of live shingles vaccine
A target trial emulation was conducted to assess the effectiveness of recombinant zoster vaccine (RZV) accounting for prior receipt of live zoster vaccine (ZVL) and immunocompetence. The results suggest individuals vaccinated with ZVL should be revaccinated with two doses of RZV.